{
    "clinical_study": {
        "@rank": "38317", 
        "arm_group": [
            {
                "arm_group_label": "Prototype 1", 
                "arm_group_type": "Experimental", 
                "description": "4mg nicotine lozenge administered orally as a single dose treatment per subject"
            }, 
            {
                "arm_group_label": "Prototype 2", 
                "arm_group_type": "Experimental", 
                "description": "4mg nicotine lozenge administered orally as a single dose treatment per subject"
            }, 
            {
                "arm_group_label": "Prototype 3", 
                "arm_group_type": "Experimental", 
                "description": "4mg nicotine lozenge administered orally as a single dose treatment per subject"
            }, 
            {
                "arm_group_label": "Reference Therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "4mg nicotine lozenge (internationally marketed) to be administered orally as a single dose treatment  per subject."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, single center, open label, single dose, four way crossover study in\n      fasted healthy male subjects to compare the pharmacokinetics of nicotine following\n      administration of 3 prototype 4mg nicotine lozenge to an internationally marketed 4mg\n      nicotine lozenge. Blood samples will be drawn at pre-specified intervals for a total of 12\n      hours post dose in each treatment session and plasma samples analyzed for nicotine levels."
        }, 
        "brief_title": "Pharmacokinetic Study of 4 mg Nicotine Lozenge.", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Smoking Cessation", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - smoked commercially-manufactured cigarettes daily for the preceding 12 months and\n        routinely smokes first cigarette within 30mins of awakening.\n\n        Exclusion Criteria:\n\n          -  inability to refrain from smoking during confinement period, smoking tobacco in any\n             other form other than commercially manufactured cigarettes, subject has used chewing\n             tobacco or other tobacco products other than commercially manufactured cigarettes\n             within 7 days of dosing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669122", 
            "org_study_id": "RH01333"
        }, 
        "intervention": {
            "arm_group_label": [
                "Reference Therapy", 
                "Prototype 3", 
                "Prototype 2", 
                "Prototype 1"
            ], 
            "description": "4 mg nicotine lozenge experimental", 
            "intervention_name": "nicotine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Nicotine", 
                "Nicotine polacrilex"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ahmedabad", 
                    "country": "India", 
                    "state": "Gujarat", 
                    "zip": "380 061"
                }, 
                "name": "Lambda Therapeutic Research Ltd"
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Cross-Over, Single Dose Pharmacokinetic Study of 4mg Nicotine Lozenges.", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India (DCGI)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the plasma concentration time curve from zero and extrapolated to the time of last quantifiable sample was determined from plasma concentration time profile of nicotine. AUC(0 -t) was based on the baseline adjusted nicotine plasma concentration data.", 
                "measure": "Area under the curve from time 0 to t, AUC (0-t)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were collected pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post dosing"
            }, 
            {
                "description": "Maximum plasma nicotine concentration was determined from plasma-concentration time profiles. Cmax was based on the baseline adjusted nicotine plasma concentration data.", 
                "measure": "Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were collected pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669122"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma nicotine concentration-time curve from zero extrapolated to infinity was determined. AUC(0-inf) was based on the baseline adjusted nicotine plasma concentration data.", 
                "measure": "AUC(0-inf)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were collected pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post dosing"
            }, 
            {
                "description": "Tmax was determined from plasma concentration time profiles. Tmax was based on the baseline adjusted nicotine plasma concentration data.", 
                "measure": "Time to maximum plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were collected pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post dosing"
            }, 
            {
                "description": "Elimination rate constant for nicotine was calculated. Kel was based on the baseline adjusted nicotine plasma concentration data.", 
                "measure": "Rate of elimination (Kel)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were collected pre-dose at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post dosing"
            }, 
            {
                "description": "Half-life of elimination of nicotine was determined. t1/2 was based on the baseline adjusted nicotine plasma concentration data.", 
                "measure": "Plasma half life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were collected pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post dosing"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}